NVC-422 is a topical, non-antibiotic, fast-acting, broad-spectrum anti-microbial, which exhibits the potential to prevent the growth of urinary pathogens, including Proteus and others. The use of a catheter irrigation solution that can prevent biofilm formation and encrustation leading to blockage may keep the catheter patent longer, resulting in fewer catheter changes, potentially lower incidence of UTIs, and better patient quality of life. The study population will include male and female spinal cord injury (SCI) and other neurogenic bladder patients with chronic indwelling transurethral urinary catheters who have a recent repeated history of urinary catheter encrustation and/or blockage. Subjects will receive two treatment regimens: one treatment regimen with NVC-422 sterile irrigation solution and one treatment regimen with sterile saline irrigation solution. Each treatment regimen will consist of a total of 8 treatments, with a washout period between treatment regimens.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
67
0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
Los Amigos Research and Education Institute (LAREI)
Downey, California, United States
Specialists in Urology
Naples, Florida, United States
Kessler Institute for Rehabilitation
West Orange, New Jersey, United States
Carolinas Medical Center
Charlotte, North Carolina, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
McGuire Veterans Affairs Medical Center
Richmond, Virginia, United States
Integrity Medical Research
Mountlake Terrace, Washington, United States
Catheter patency following treatment
Cross sectional area (percent of open area that is not encrusted) will be determined at pre-selected loci on the catheter
Time frame: 26 days
Incidence of catheter blockage requiring early removal
Catheters removed prior to completion of treatment regimen will be assessed for each treatment group
Time frame: 26 days
Assessment of biofilm of catheter
Qualitative and quantitative assessment of biofilm of catheter will be determined for all catheters removed
Time frame: 26 days
Assessment of encrustation of catheter
Qualitative and quantitative assessment of encrustation of catheter will be determined for all catheters removed
Time frame: 26 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.